Attention Long-term West Pharmaceutical Services, Inc. (WST) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf

Philadelphia, Pennsylvania--(Newsfile Corp. - May 6, 2025) - Grabar Law Office is investigating whether certain officers and directors of West Pharmaceutical Services, Inc. (NYSE: WST) breached the fiduciary duties they owed to the company.

If you are a long-term West shareholder who has held West shares since before February 16, 2023, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Visit https://grabarlaw.com/the-latest/west-shareholder-investigation/, or contact Joshua Grabar at jgrabar@grabarlaw.com, or 267-507-6048 to learn more.

Why? An underlying securities fraud class action complaint alleges that West, via certain of its officers, failed to disclose that: (a) while claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with long-standing customers; and (d) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.

As alleged in the underlying class action complaint, the truth about the fraud was revealed with a series of disclosures culminating on February 13, 2025, when West issued extremely weak 2025 revenue and earnings forecasts. West attributed the disappointing guidance in part to contract manufacturing headwinds, including the loss of two major continuing glucose monitoring customers that had begun transitioning to in-house manufacturing of next-generation devices after West "made the decision to not participate going forward as our financial thresholds cannot be achieved." West also revealed that its SmartDose wearable injector devices would be "margin-dilutive" in 2025 and that it would be "taking steps to improve [its SmartDose] economics, and all options are on the table." On this news, West's stock dropped 38 percent.

What You Can Do Now: Current West shareholders who have continuously held West stock since prior to February 16, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them. If you would like to learn more about this matter at no cost to you, you are encouraged to visit https://grabarlaw.com/the-latest/west-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

#WestPharmaceutical #WST

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250970